{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:57:32Z","timestamp":1793883452271,"version":"4.7.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cmi.2018.01.029","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T01:47:29Z","timestamp":1518054449000},"page":"S2-S9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"S2","title":["ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction)"],"prefix":"10.1016","volume":"24","author":[{"given":"M.","family":"Fern\u00e1ndez-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Meije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Akan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Carratal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Delaloye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2018.01.029_bib1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.01.029_bib2","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.01.029_bib3","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.cmi.2017.12.027","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)","volume":"24","author":"Aguilar-Company","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.01.029_bib4","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.01.029_bib5","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.01.029_bib6","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.01.029_bib7","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.01.029_bib8","first-page":"111","article-title":"Paul Ehrlich (1854\u20131915) and his contributions to the foundation and birth of translational medicine","volume":"8","author":"Valent","year":"2016","journal-title":"J\u00a0Innate Immun"},{"key":"10.1016\/j.cmi.2018.01.029_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.029_bib10","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.01.029_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A\u00a0comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cmi.2018.01.029_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2018.01.029_bib13","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.029_bib14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fimmu.2015.00605","article-title":"Natural killer cell\u2013based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity","volume":"6","author":"Dahlberg","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2018.01.029_bib15","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1021\/nn5014484","article-title":"A\u00a0nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival","volume":"8","author":"Kim","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.cmi.2018.01.029_bib16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/cgt.2014.47","article-title":"Gene-directed enzyme prodrug therapy for localized chemotherapeutics in allograft and xenograft tumor models","volume":"21","author":"Carruthers","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.cmi.2018.01.029_bib17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.molonc.2014.08.001","article-title":"Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy","volume":"9","author":"Albarakati","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.cmi.2018.01.029_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s13311-017-0516-0","article-title":"Oncolytic virotherapy for the treatment of malignant glioma","volume":"14","author":"Foreman","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.cmi.2018.01.029_bib19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3816\/CGC.2007.n.029","article-title":"Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy","volume":"5","author":"Amato","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.cmi.2018.01.029_bib20","first-page":"160","article-title":"Monoclonal antibodies: methods and clinical laboratory applications","volume":"1","author":"Nakamura","year":"1983","journal-title":"Clin Physiol Biochem"},{"key":"10.1016\/j.cmi.2018.01.029_bib21","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1084\/jem.170.6.2153","article-title":"The immunogenicity of chimeric antibodies","volume":"170","author":"Bruggemann","year":"1989","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.cmi.2018.01.029_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0076-6879(91)03007-4","article-title":"Humanization of monoclonal antibodies","volume":"203","author":"Gussow","year":"1991","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.cmi.2018.01.029_bib23","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2006.01.026","article-title":"Engineering of therapeutic antibodies to minimize immunogenicity and optimize function","volume":"58","author":"Presta","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.cmi.2018.01.029_bib24","series-title":"Revised monoclonal antibody nomenclature scheme","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.cmi.2018.01.029_bib25","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.cmi.2018.01.029_bib26","article-title":"Monoclonal antibodies: a review","author":"Singh","year":"2017","journal-title":"Curr Clin Pharmacol"},{"issue":"8400","key":"10.1016\/j.cmi.2018.01.029_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(84)92907-6","article-title":"Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma","volume":"2","author":"Nadler","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.01.029_bib28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/mabs.2.1.10789","article-title":"Evolution of anti-CD20 monoclonal antibody therapeutics in oncology","volume":"2","author":"Oflazoglu","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.cmi.2018.01.029_bib29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.01.029_bib30","first-page":"323","article-title":"PEGylation\u2014a well-proven strategy for the improvement of recombinant drugs","volume":"69","author":"Zundorf","year":"2014","journal-title":"Pharmazie"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.cmi.2018.01.029_bib31","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s40259-013-0064-z","article-title":"Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol","volume":"28","author":"Pasut","year":"2014","journal-title":"BioDrugs"},{"key":"10.1016\/j.cmi.2018.01.029_bib32","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/annonc\/mdw424","article-title":"Antibody drug conjugates: lessons from 20 years of clinical experience","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2018.01.029_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14728214.2017.1366447","article-title":"Emerging antibody\u2013drug conjugates for treating lymphoid malignancies","volume":"22","author":"Wolska-Washer","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.cmi.2018.01.029_bib34","first-page":"38","article-title":"Fc Engineering for developing therapeutic bispecific antibodies and novel scaffolds","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.cmi.2018.01.029_bib35","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14740338.2017.1338270","article-title":"Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab","volume":"16","author":"Wilke","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2018.01.029_bib36","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in\u00a0vitro and in\u00a0vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.cmi.2018.01.029_bib37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/187152011795347469","article-title":"BRAF as a target for cancer therapy","volume":"11","author":"Dienstmann","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.cmi.2018.01.029_bib38","first-page":"129","article-title":"Targeting of BCR-ABL: lessons learned from BCR-ABL inhibition","volume":"62","author":"Lin","year":"2016","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"10.1016\/j.cmi.2018.01.029_bib39","first-page":"887","article-title":"Update on the clinical use of kinase inhibitors in melanoma","volume":"15","author":"Cosgarea","year":"2017","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.cmi.2018.01.029_bib40","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2147\/OTT.S102573","article-title":"Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential","volume":"9","author":"Barrientos","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"10","key":"10.1016\/j.cmi.2018.01.029_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22101551","article-title":"Current development status of MEK inhibitors","volume":"22","author":"Cheng","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.cmi.2018.01.029_bib42","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0889-8588(02)00051-5","article-title":"Clinical development of mammalian target of rapamycin inhibitors","volume":"16","author":"Dancey","year":"2002","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.cmi.2018.01.029_bib43","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0952-7915(00)00228-4","article-title":"Signaling by type I and II cytokine receptors: ten years after","volume":"13","author":"Gadina","year":"2001","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cmi.2018.01.029_bib44","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.tips.2014.09.007","article-title":"Advances in kinase targeting: current clinical use and clinical trials","volume":"35","author":"Rask-Andersen","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.cmi.2018.01.029_bib45","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cmi.2018.01.029_bib46","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1002\/jps.24113","article-title":"Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors","volume":"103","author":"Shao","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.cmi.2018.01.029_bib47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","article-title":"Alterations in immune function with biologic therapies for autoimmune disease","volume":"137","author":"Her","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cmi.2018.01.029_bib48","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","article-title":"Adverse reactions to biologic agents and their medical management","volume":"10","author":"Boyman","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.cmi.2018.01.029_bib49","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00040-08","article-title":"Infectious complications associated with monoclonal antibodies and related small molecules","volume":"22","author":"Salvana","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2018.01.029_bib50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12016-013-8378-7","article-title":"The hyper IgM syndromes","volume":"46","author":"Qamar","year":"2014","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.cmi.2018.01.029_bib51","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10875-013-9980-4","article-title":"First report of the hyper-IgM syndrome registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes","volume":"34","author":"Cabral-Marques","year":"2014","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.cmi.2018.01.029_bib52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/ar3893","article-title":"Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy","volume":"14","author":"Huppler","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cmi.2018.01.029_bib53","article-title":"Alemtuzumab for multiple sclerosis","volume":"4","author":"Riera","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2018.01.029_bib54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/2040620712458949","article-title":"Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use","volume":"3","author":"Warner","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.cmi.2018.01.029_bib55","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.01.029_bib56","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.01.029_bib57","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cid\/cix325","article-title":"Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation","volume":"65","author":"Prestes","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.01.029_bib58","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.4049\/jimmunol.174.11.7446","article-title":"The influence of age on T cell generation and TCR diversity","volume":"174","author":"Naylor","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2018.01.029_bib59","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.01.029_bib60","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cmi.2018.01.029_bib61","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2018.01.029_bib62","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2018.01.029_bib63","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2018.01.029_bib64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.rdc.2016.09.005","article-title":"Opportunistic infections in biological therapy, risk and prevention","volume":"43","author":"Bryant","year":"2017","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18301472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18301472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T09:11:25Z","timestamp":1668762685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18301472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":64,"alternative-id":["S1198743X18301472"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2018.01.029","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction)","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2018.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}